BioCryst Pharmaceuticals, Inc. Market Research Report

Company Overview

• Name: BioCryst Pharmaceuticals, Inc.

• Mission: Helping restore a sense of freedom for patients with hereditary angioedema (HAE) and other rare diseases through the development of novel medicines.

• Founded: 1986

• Founders: William Spencer, III; Charles Bugg, MD; John Montgomery, PhD

• Key People:

• Jon Stonehouse, Chief Executive Officer

• Bill Sheridan, MD, Chief Medical Officer

• Other members: Chief People Officer, Chief Discovery Officer, Chief Legal Officer, Chief Communications Officer, Chief Financial Officer, Chief Business Development Officer, Chief Commercial Officer, Chief Strategy Officer, Chief Regulatory Officer, Chief Data and Insights Officer, Chief Development Officer, Chief Research & Development Officer.

• Headquarters: Durham, North Carolina, USA with European headquarters in Dublin, Ireland.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: BioCryst is recognized for its expertise in the structure-guided drug design, particularly in developing oral small-molecule and protein therapeutics for the treatment of hereditary angioedema (HAE) and other rare diseases.

Products

ORLADEYO® (berotralstat)

• Description: Oral plasma kallikrein inhibitor.

• Key Features: Used for the prevention of acute attacks in patients with hereditary angioedema (HAE).

RAPIVAB® (peramivir injection)

• Description: An injected antiviral medication.

• Key Features: Primarily used for the treatment of influenza.

Pipeline Products

• BCX17725: Protein Therapeutic for Netherton Syndrome.

• Avoralstat: Ocular Plasma Kallikrein Inhibitor for Diabetic Macular Edema (DME).

• Oral C5 Inhibitor: In development for complement-mediated diseases.

• Oral C2 Inhibitor: In development for complement-mediated diseases.

• Bifunctional Complement Inhibitor: In development for complement-mediated diseases.

Recent Developments

• New Products Launched: ORLADEYO® (berotralstat) was launched following FDA approval in December 2020 and has since been launched in multiple global markets.

• Pipeline Strategy: Refined to focus on complement-mediated diseases with the development of a next-generation oral factor D inhibitor, BCX10013.

• Partnerships: BioCryst has formed various partnerships for global commercialization of ORLADEYO® (berotralstat) outside the United States with companies like Torii Pharmaceutical, Neopharm Group, NewBridge Pharmaceuticals, Pint Pharma, and Swixx BioPharma.

• Clinical Trials: Initiated pivotal trials for oral factor D inhibitor, BCX9930, in complement-mediated diseases.

• Regulatory Approvals: Obtained FDA approval for RAPIVAB® and commenced expansion in global markets.

No other recent developments or new features for existing products are provided in the data.

This report reflects the data available related to BioCryst Pharmaceuticals, Inc. as gathered from the provided company data.